Immune checkpoint inhibitor efficacy against glioblastoma may decrease with dexamethasone

Bottom Line: Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research Author: David A. Reardon, MD, clinical director of the […]

Next generation BRAF inhibitor cancer drug shows promise in early patient trial

A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial presented at the 32nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online. The BRAF gene is involved in telling healthy cells when to grow and form new cells, […]

Inhibitor of KRAS gene mutation shows promise in lung, bowel and other solid tumors

IMAGE: Patient CT scans before and after treatment with adagrasib. Yellow arrow marks location of main tumor. view more  Credit: Pasi A. Jänne New results from early clinical trials of a drug that targets a cancer-causing mutation in the KRAS gene have shown that it can shrink tumours and is well-tolerated by patients. In two presentations […]

Targeted inhibitor of mutated KRAS gene shows promise in lung, bowel, & other solid tumors

IMAGE: Pasi A. Jänne, MD, PhD view more  Credit: Dana-Farber Cancer Institute A novel agent that targets a mutated form of the KRAS gene – the most commonly altered oncogene in human cancers and one long considered “undruggable” – shrank tumors in most patients in a clinical trial with manageable side effects, researchers reported today at […]